News & Videos - ARDELYX INC.

Thinking about buying stock in Angion Biomedica, Ardelyx, AMC Entertainment, Applied Therapeutics, or Wisekey International Holding ? PR Newswire NEW YORK, Jan. 9, 2024 NEW YORK , Jan. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELTX, ARDX, AMC, APLT, and WKEY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ELTX:...

Thinking about buying stock in Annexin Pharmaceuticals, Ardelyx, Fusion Pharmaceuticals, Aurora Technology Acquisition, or Terran Orbital? PR Newswire NEW YORK, Dec. 21, 2023 NEW YORK , Dec. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANNX, ARDX, FUSN, ATAK, and LLAP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ANNX:...

Thinking about buying stock in Perfect Corp, UP Fintech, Theseus Pharmaceuticals, Reliance Sekuritas Indonesia, or Ardelyx? PR Newswire NEW YORK, Nov. 27, 2023 NEW YORK , Nov. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PERF, TIGR, THRX, RELI, and ARDX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PERF:...

Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics? PR Newswire NEW YORK, Oct. 20, 2023 NEW YORK , Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, RIVN, FEMY, LCID, and OTLK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ARDX:...

Thinking about buying stock in Ardelyx, RVL Pharmaceuticals, Wheeler Real Estate Investment Trust, Troika Media Group, or AT&T? PR Newswire NEW YORK, Oct. 19, 2023 NEW YORK , Oct. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, RVLP, WHLR, TRKA, and T. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ARDX:...

Thinking about buying stock in Joby Aviation, Aurora Innovation, Terawulf, Ardelyx, or Immunic? PR Newswire NEW YORK, July 27, 2023 NEW YORK , July 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JOBY, AUR, WULF, ARDX, and IMUX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. JOBY:...

Thinking about buying stock in Ardelyx, C3.ai, SoundHound AI, BigBear.ai, or Veritone? PR Newswire NEW YORK, March 3, 2023 NEW YORK , March 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, AI, SOUN, BBAI, and VERI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ARDX:...

Ardelyx, Inc. Reports Employment Inducement Grants PR Newswire WALTHAM, Mass., Feb. 2, 2023 WALTHAM, Mass. , Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on January 27, 2023 , the compensation committee of the company's board of directors granted 23 new non-executive employees options to...

Thinking about buying stock in Esports Entertainment, Ardelyx, Gaotu Techedu, Hoth Therapeutics, or IQIYI? PR Newswire NEW YORK, Dec. 29, 2022 NEW YORK , Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMBL, ARDX, GOTU, HOTH, and IQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. GMBL:...

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) PR Newswire WALTHAM, Mass., Dec. 29, 2022 Office of New Drugs directs the Division of Cardiology and Nephrology to work with Ardelyx to develop a label to support the commercialization of XPHOZAH; Ardelyx to resubmit NDA in the first half of 2023 Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism Conference call to be held Dec. 29, 2022 , at 8:00 AM ET WALTHAM, Mass. , Dec....

Ardelyx, Inc. Reports Employment Inducement Grants PR Newswire WALTHAM, Mass., Dec. 23, 2022 WALTHAM, Mass. , Dec. 23, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on December 16, 2022 , the compensation committee of the company's board of directors granted 17 new non-executive employees options to...

Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis PR Newswire WALTHAM, Mass., Dec. 16, 2022 WALTHAM, Mass. , Dec. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, provided an update regarding the appeal to the...

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference PR Newswire WALTHAM, Mass., Nov. 22, 2022 WALTHAM, Mass. , Nov. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34 th Annual Piper Sandler Healthcare Conference on...

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis PR Newswire WALTHAM, Mass., Nov. 16, 2022 The Advisory Committee voted 9:4 in favor of XPHOZAH as a monotherapy and 10:2 in favor of XPHOZAH in combination with phosphate binders The Office of New Drugs is expected to provide a response to Ardelyx's appeal within thirty (30) days If approved,...

Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis PR Newswire WALTHAM, Mass., Nov. 16, 2022 WALTHAM, Mass. , Nov. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that...

National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels PR Newswire WALTHAM, Mass. and NEW YORK, Nov. 4, 2022 Majority of survey respondents call for new treatments to help manage phosphorus levels WALTHAM, Mass. and NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on...

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights PR Newswire WALTHAM, Mass., Nov. 3, 2022 Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass. , Nov. 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the third...

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis PR Newswire WALTHAM, Mass., Nov. 3, 2022 XPHOZAH monotherapy lowers serum phosphorus with early responders maintaining response with continued treatment XPHOZAH monotherapy meaningfully reduced serum phosphorus in patients with severe...

Ardelyx, Inc. Reports Employment Inducement Grants PR Newswire WALTHAM, Mass., Nov. 2, 2022 WALTHAM, Mass. , Nov. 2, 2022 /PRNewswire/ --Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on October 26, 2022 , the compensation committee of the company's board of directors granted three new non-executive employees options to...

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan PR Newswire WALTHAM, Mass., Oct. 31, 2022 Ardelyx to receive an aggregate of $35 million in milestone payments and payments associated with the recent amendment of the license agreement WALTHAM, Mass. , Oct. 31, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...